Details for New Drug Application (NDA): 077381
✉ Email this page to a colleague
NDA 077381 describes NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, which is a drug marketed by Aurobindo Pharma, Dr Reddys Labs Inc, and Perrigo, and is included in three NDAs. It is available from ten suppliers. Additional details are available on the NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE profile page.
The generic ingredient in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.
The generic ingredient in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.
Summary for 077381
| Tradename: | NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE |
| Applicant: | Dr Reddys Labs Inc |
| Ingredient: | naproxen sodium; pseudoephedrine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 220MG;120MG | ||||
| Approval Date: | Sep 27, 2006 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
